JP2020506946A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506946A5
JP2020506946A5 JP2019542502A JP2019542502A JP2020506946A5 JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5 JP 2019542502 A JP2019542502 A JP 2019542502A JP 2019542502 A JP2019542502 A JP 2019542502A JP 2020506946 A5 JP2020506946 A5 JP 2020506946A5
Authority
JP
Japan
Prior art keywords
oxo
carboxamide
dihydropyridazine
chlorophenyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542502A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128826B2 (ja
JP2020506946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/052627 external-priority patent/WO2018146010A1/en
Publication of JP2020506946A publication Critical patent/JP2020506946A/ja
Publication of JP2020506946A5 publication Critical patent/JP2020506946A5/ja
Application granted granted Critical
Publication of JP7128826B2 publication Critical patent/JP7128826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542502A 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類 Active JP7128826B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17155406.6 2017-02-09
EP17155406 2017-02-09
EP17202882 2017-11-21
EP17202882.1 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (en) 2017-02-09 2018-02-02 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2020506946A JP2020506946A (ja) 2020-03-05
JP2020506946A5 true JP2020506946A5 (enExample) 2021-03-11
JP7128826B2 JP7128826B2 (ja) 2022-08-31

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542502A Active JP7128826B2 (ja) 2017-02-09 2018-02-02 がん治療のための2-ヘテロアリール-3-オキソ-2,3-ジヒドロピリダジン-4-カルボキサミド類

Country Status (39)

Country Link
US (3) US12522594B2 (enExample)
EP (1) EP3580211B1 (enExample)
JP (1) JP7128826B2 (enExample)
KR (1) KR102627266B1 (enExample)
CN (3) CN116531380B (enExample)
AU (1) AU2018217860B2 (enExample)
BR (1) BR112019016497A2 (enExample)
CA (1) CA3052718A1 (enExample)
CL (1) CL2019002255A1 (enExample)
CO (1) CO2019008684A2 (enExample)
CR (1) CR20190364A (enExample)
CU (1) CU24564B1 (enExample)
CY (1) CY1124484T1 (enExample)
DK (1) DK3580211T3 (enExample)
DO (1) DOP2019000206A (enExample)
EC (1) ECSP19057713A (enExample)
ES (1) ES2847162T3 (enExample)
GE (2) GEP20217281B (enExample)
HR (1) HRP20210143T1 (enExample)
HU (1) HUE053191T2 (enExample)
IL (1) IL268469B (enExample)
JO (1) JOP20190193B1 (enExample)
LT (1) LT3580211T (enExample)
MA (1) MA47447B1 (enExample)
MX (1) MX2019009571A (enExample)
MY (1) MY198510A (enExample)
NI (1) NI201900085A (enExample)
PE (1) PE20191496A1 (enExample)
PH (1) PH12019501846A1 (enExample)
PL (1) PL3580211T3 (enExample)
RS (1) RS61401B1 (enExample)
SA (1) SA519402422B1 (enExample)
SG (1) SG11201907232XA (enExample)
SI (1) SI3580211T1 (enExample)
TW (1) TWI770113B (enExample)
UA (1) UA124507C2 (enExample)
UY (1) UY37606A (enExample)
WO (1) WO2018146010A1 (enExample)
ZA (1) ZA201905902B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892666A1 (ru) * 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
CN116531380B (zh) 2017-02-09 2025-11-07 拜耳股份公司 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (en) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
CA3164474A1 (en) 2019-12-16 2021-06-24 Bayer Aktiengesellschaft Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
KR20220153595A (ko) 2020-02-26 2022-11-18 재규어 테라퓨틱스 피티이 리미티드 AhR 신호전달의 조절에 유용한 피리도피리미딘 유도체
US20230150970A1 (en) * 2020-03-27 2023-05-18 Dong-A St Co., Ltd. Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
US12570638B2 (en) 2020-05-20 2026-03-10 Sail Biomedicines, Inc. Fused imidazole derivatives as AHR antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221A (zh) * 2020-11-27 2022-05-27 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426A (zh) * 2020-12-28 2022-07-01 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
CN118234710A (zh) * 2021-09-14 2024-06-21 元启(苏州)生物制药有限公司 2-芳基或杂芳基-3-氧代-4-甲酰胺-6-环-二氢吡嗪芳基烃受体调节剂和其在治疗疾病和病症中的用途
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
KR100657189B1 (ko) * 1998-08-14 2006-12-14 니혼노야쿠가부시키가이샤 피리다지논 유도체 및 이를 함유하는 의약 조성물
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
CA2742411A1 (en) 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
CA2586420A1 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
WO2006082952A1 (ja) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited アミド化合物
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
US7855310B2 (en) 2006-05-03 2010-12-21 Symrise Gmbh & Co. Kg AH receptor antagonists
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
DE102006054205A1 (de) 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
AU2007336781C1 (en) * 2006-12-21 2014-10-09 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
BRPI0819696B1 (pt) 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
EA035288B1 (ru) 2010-07-27 2020-05-25 Трастис Оф Бостон Юниверсити МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US20170173008A1 (en) 2014-03-19 2017-06-22 President And Fellows Of Harvard College Antimicrobial agents and screening methods
EA201892666A1 (ru) * 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
CN116531380B (zh) * 2017-02-09 2025-11-07 拜耳股份公司 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
WO2019101647A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
CA3082855A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
EP3713931B1 (en) 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2020061377A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
US12358918B2 (en) 2018-11-14 2025-07-15 The Broad Institute, Inc. Aryl hydrocarbon receptor (AHR) activator compounds as cancer therapeutics
EP4013508A1 (en) 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2021074279A1 (en) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Spiro-fused tricyclic map4k1 inhibitors
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
US20240174683A1 (en) 2021-02-05 2024-05-30 Bayer Aktiengesellschaft Map4k1 inhibitors

Similar Documents

Publication Publication Date Title
HRP20210143T1 (hr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za liječenje raka
RU2404164C2 (ru) Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2017530185A5 (enExample)
JP2019537571A5 (enExample)
JP2019533694A5 (enExample)
JP2019518036A5 (enExample)
JP2016534023A5 (enExample)
JP2016528201A5 (enExample)
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2017508763A5 (enExample)
RU2014147191A (ru) Амидопроизводные как блокаторы ttx-s
JP2017537948A5 (enExample)
JP2017511794A5 (enExample)
RU2004129780A (ru) Производные аминоиндазолов, способ получения и промежуточные продукты этого способа в качестве лекарственных средств и содержащие их фармацевтические композиции
RU2019133530A (ru) ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2018522847A5 (enExample)
JP2019532072A5 (enExample)
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
JP2015514679A5 (enExample)
RU2014147243A (ru) Производные пирролопиридинона в качестве ttx-s блокаторов
JP2021520340A5 (enExample)
JP2016534143A5 (enExample)